Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 2,515 |
| 2 | Bristol Myers Squibb Co | 1,930 |
| 3 | Takeda Pharmaceutical Co Ltd | 1,494 |
| 4 | Novartis AG | 1,218 |
| 5 | C.H. Boehringer Sohn AG and Co KG | 906 |
| 6 | Sanofi SA | 782 |
| 7 | Johnson and Johnson | 656 |
| 8 | Gilead Sciences Inc | 532 |
| 9 | AstraZeneca PLC | 505 |
| 10 | Organon and Co | 483 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 30,215 |
| 2 | A61K | Medicinal preparations | 25,846 |
| 3 | C07D | Heterocyclic compounds | 17,298 |
| 4 | C07K | Peptides | 3,477 |
| 5 | C07C | Acyclic and carbocyclic compounds | 2,747 |
| 6 | Y02A | Climate change adaptation | 1,909 |
| 7 | C12N | Microorganisms, enzymes | 1,565 |
| 8 | G01N | Investigating / analysing materials | 1,540 |
| 9 | C07B | General methods of organic chemistry | 1,342 |
| 10 | C07F | Organometallic compounds | 1,112 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Avapro dispersible tablet and preparation method thereof | 2010 | 8 | |
| Avapro dispersible tablet and preparation method thereof | 2013 | 0 | |
| Aprovel | 1998 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 53 |
| 2017 | 29 |
| 2018 | 32 |
| 2019 | 34 |
| 2020 | 41 |
| 2021 | 28 |
| 2022 | 28 |
| 2023 | 40 |
| 2024 | 28 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Karin Malmqvist | Karolinska Institutet | 19 |
| 2 | Thomas Kahan | Karolinska Institutet | 15 |
| 3 | Peter Bramlage | Technische Universität Dresden | 14 |
| 4 | Inder S. Anand | University of Minnesota | 12 |
| 5 | John J.V. McMurray | University of Glasgow | 12 |
| 6 | Michel Burnier | Hôpital Orthopédique de la Suisse Romande | 12 |
| 7 | Hans‐Henrik Parving | Steno Diabetes Centers | 10 |
| 8 | James R. Sowers | University of Missouri | 9 |
| 9 | Andrew Palmer | Center for Outcomes Research and Clinical Epidemiology | 9 |
| 10 | Peter E. Carson | Georgetown University | 9 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes | 2001 | 6034 | Blood Pressure and Hypertension Studies |
| The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes | 2001 | 2901 | Blood Pressure and Hypertension Studies |
| [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. | 2001 | 2531 | Blood Pressure and Hypertension Studies |
| Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | 2008 | 1956 | Atrial Fibrillation Management and Outcomes |
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | 2011 | 1438 | Atrial Fibrillation Management and Outcomes |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Avapro?
Which companies hold the most patents related to Avapro?
What are the most cited research papers on Avapro and their topics?
Who are the most prolific authors publishing on Avapro?
How has patent and publication activity for Avapro changed over time?